一项关于2%托法替布乳膏联合窄谱中波紫外线治疗面部白癜风的初步研究。 - Suppr

Suppr

超能文献

A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo.

作者信息

McKesey Jacqueline, Pandya Amit G

机构信息

Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas.

出版信息

J Am Acad Dermatol. 2019 Aug;81(2):646-648. doi: 10.1016/j.jaad.2019.04.032. Epub 2019 Apr 19.

DOI:10.1016/j.jaad.2019.04.032

PMID:31009664

Abstract

摘要

相似文献

A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo.

J Am Acad Dermatol. 2019 Aug;81(2):646-648. doi: 10.1016/j.jaad.2019.04.032. Epub 2019 Apr 19.

Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy.

JAMA Dermatol. 2018 Mar 1;154(3):370-371. doi: 10.1001/jamadermatol.2017.5778.

Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.

J Am Acad Dermatol. 2017 Oct;77(4):675-682.e1. doi: 10.1016/j.jaad.2017.05.043. Epub 2017 Aug 18.

Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.

J Am Acad Dermatol. 2017 Jul;77(1):167-170. doi: 10.1016/j.jaad.2017.03.024.

Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.

JAMA Dermatol. 2015 Oct;151(10):1110-2. doi: 10.1001/jamadermatol.2015.1520.

Tofacitinib therapy for children with severe alopecia areata.

J Am Acad Dermatol. 2019 Apr;80(4):1164-1166. doi: 10.1016/j.jaad.2018.12.041. Epub 2019 Jan 8.

Successful treatment of resistant lichen planopilaris with topical tofacitinib monotherapy.

Ann Dermatol Venereol. 2024 Sep;151(3):103303. doi: 10.1016/j.annder.2024.103303. Epub 2024 Aug 17.

[Pharmacology profile and clinical findings of tofacitinib citrate (Xeljanz® tablet 5 mg)].

Nihon Yakurigaku Zasshi. 2014 Sep;144(3):133-41. doi: 10.1254/fpj.144.133.

Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child.

Pediatr Dermatol. 2020 Jul;37(4):754-755. doi: 10.1111/pde.14159. Epub 2020 Apr 7.

Tofacitinib Treatment for Pretibial Myxedema.

JAMA Dermatol. 2024 May 1;160(5):578-580. doi: 10.1001/jamadermatol.2024.0344.

引用本文的文献

Efficacy and Safety of JAK Inhibitors in the Management of Vitiligo: A Systematic Review and Meta-analysis.

Dermatol Ther (Heidelb). 2025 May 7. doi: 10.1007/s13555-025-01397-z.

Short-term efficacy and safety of upadacitinib combined with 308 excimer light versus upadacitinib alone and 308 excimer light alone in patients with progressing facial vitiligo.

Arch Dermatol Res. 2025 Jan 16;317(1):252. doi: 10.1007/s00403-024-03717-3.

Low-Dose Baricitinib Plus Narrow-Band Ultraviolet B for the Treatment of Progressive Non-Segmental Vitiligo: A Prospective, Controlled, Open-Label Study.

Pigment Cell Melanoma Res. 2025 Jan;38(1):e13209. doi: 10.1111/pcmr.13209. Epub 2024 Oct 23.

Up-and-Coming Drugs for the Treatment of Vitiligo.

Ann Dermatol. 2024 Aug;36(4):197-208. doi: 10.5021/ad.24.038.

Targeted therapy for immune mediated skin diseases. What should a dermatologist know?

An Bras Dermatol. 2024 Jul-Aug;99(4):546-567. doi: 10.1016/j.abd.2023.10.002. Epub 2024 Mar 22.

Tofacitinib 2% Gel in Childhood Vitiligo: Report of a Case of Significant Improvement.

Indian J Dermatol. 2023 Nov-Dec;68(6):705-706. doi: 10.4103/ijd.ijd_482_23. Epub 2024 Jan 9.

Vitiligo: Pathogenesis and New and Emerging Treatments.

Int J Mol Sci. 2023 Dec 9;24(24):17306. doi: 10.3390/ijms242417306.

Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics.

J Clin Med. 2023 Dec 4;12(23):7486. doi: 10.3390/jcm12237486.

Intravenous immunoglobulin-refractory necrobiotic xanthogranuloma successfully treated with tofacitinib 2% cream.

JAAD Case Rep. 2022 Dec 15;32:41-43. doi: 10.1016/j.jdcr.2022.12.002. eCollection 2023 Feb.

Current Concepts of Vitiligo Immunopathogenesis.

Biomedicines. 2022 Jul 8;10(7):1639. doi: 10.3390/biomedicines10071639.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo.

作者信息

McKesey Jacqueline, Pandya Amit G

机构信息

Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas.

出版信息

J Am Acad Dermatol. 2019 Aug;81(2):646-648. doi: 10.1016/j.jaad.2019.04.032. Epub 2019 Apr 19.

DOI:10.1016/j.jaad.2019.04.032

PMID:31009664

Abstract

摘要

相似文献

A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo.

J Am Acad Dermatol. 2019 Aug;81(2):646-648. doi: 10.1016/j.jaad.2019.04.032. Epub 2019 Apr 19.

Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy.

JAMA Dermatol. 2018 Mar 1;154(3):370-371. doi: 10.1001/jamadermatol.2017.5778.

Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.

J Am Acad Dermatol. 2017 Oct;77(4):675-682.e1. doi: 10.1016/j.jaad.2017.05.043. Epub 2017 Aug 18.

Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.

J Am Acad Dermatol. 2017 Jul;77(1):167-170. doi: 10.1016/j.jaad.2017.03.024.

Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.

JAMA Dermatol. 2015 Oct;151(10):1110-2. doi: 10.1001/jamadermatol.2015.1520.

Tofacitinib therapy for children with severe alopecia areata.

J Am Acad Dermatol. 2019 Apr;80(4):1164-1166. doi: 10.1016/j.jaad.2018.12.041. Epub 2019 Jan 8.

Successful treatment of resistant lichen planopilaris with topical tofacitinib monotherapy.

Ann Dermatol Venereol. 2024 Sep;151(3):103303. doi: 10.1016/j.annder.2024.103303. Epub 2024 Aug 17.

[Pharmacology profile and clinical findings of tofacitinib citrate (Xeljanz® tablet 5 mg)].

Nihon Yakurigaku Zasshi. 2014 Sep;144(3):133-41. doi: 10.1254/fpj.144.133.

Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child.

Pediatr Dermatol. 2020 Jul;37(4):754-755. doi: 10.1111/pde.14159. Epub 2020 Apr 7.

Tofacitinib Treatment for Pretibial Myxedema.

JAMA Dermatol. 2024 May 1;160(5):578-580. doi: 10.1001/jamadermatol.2024.0344.

引用本文的文献

Efficacy and Safety of JAK Inhibitors in the Management of Vitiligo: A Systematic Review and Meta-analysis.

Dermatol Ther (Heidelb). 2025 May 7. doi: 10.1007/s13555-025-01397-z.

Short-term efficacy and safety of upadacitinib combined with 308 excimer light versus upadacitinib alone and 308 excimer light alone in patients with progressing facial vitiligo.

Arch Dermatol Res. 2025 Jan 16;317(1):252. doi: 10.1007/s00403-024-03717-3.

Low-Dose Baricitinib Plus Narrow-Band Ultraviolet B for the Treatment of Progressive Non-Segmental Vitiligo: A Prospective, Controlled, Open-Label Study.

Pigment Cell Melanoma Res. 2025 Jan;38(1):e13209. doi: 10.1111/pcmr.13209. Epub 2024 Oct 23.

Up-and-Coming Drugs for the Treatment of Vitiligo.

Ann Dermatol. 2024 Aug;36(4):197-208. doi: 10.5021/ad.24.038.

Targeted therapy for immune mediated skin diseases. What should a dermatologist know?

An Bras Dermatol. 2024 Jul-Aug;99(4):546-567. doi: 10.1016/j.abd.2023.10.002. Epub 2024 Mar 22.

Tofacitinib 2% Gel in Childhood Vitiligo: Report of a Case of Significant Improvement.

Indian J Dermatol. 2023 Nov-Dec;68(6):705-706. doi: 10.4103/ijd.ijd_482_23. Epub 2024 Jan 9.

Vitiligo: Pathogenesis and New and Emerging Treatments.

Int J Mol Sci. 2023 Dec 9;24(24):17306. doi: 10.3390/ijms242417306.

Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics.

J Clin Med. 2023 Dec 4;12(23):7486. doi: 10.3390/jcm12237486.

Intravenous immunoglobulin-refractory necrobiotic xanthogranuloma successfully treated with tofacitinib 2% cream.

JAAD Case Rep. 2022 Dec 15;32:41-43. doi: 10.1016/j.jdcr.2022.12.002. eCollection 2023 Feb.

Current Concepts of Vitiligo Immunopathogenesis.

Biomedicines. 2022 Jul 8;10(7):1639. doi: 10.3390/biomedicines10071639.